None listed
Conditions
Brief summary
To determine the dose duration-response using Eumovate cream in healthy volunteers.
Interventions
Multiple dose study where each participant attends a single treatment session and receives Eumovate cream (clobetasone butyrate 0.5 mg/g (0.05% w/w)) at various dose durations. The intervention for this trial is the Reference Listed Drug (RLD) of Eumovate Cream (clobetasone butyrate 0.5 mg/g (0.05% w/w)).
Subjects will be healthy subjects who have shown a vasoconstriction response to a single dose of Eumovate cream. There will be 12 sites in total (6 on each arm) where 4 sites will be treated w
Multiple dose study where each participant attends a single treatment session and receives Eumovate cream (clobetasone butyrate 0.5 mg/g (0.05% w/w)) at various dose durations. The intervention for this trial is the Reference Listed Drug (RLD) of Eumovate Cream (clobetasone butyrate 0.5 mg/g (0.05% w/w)). Subjects will be healthy subjects who have shown a vasoconstriction response to a single dose of Eumovate cream. There will be 12 sites in total (6 on each arm) where 4 sites will be treated with the cream and 2 will be untreated control sites. The 8 treated sites (4 on each arm) will have 10 mg of cream applied at various dose-durations at 6, 4, 2, 1.5, 1, 0.75, 0.5 and 0.25 hours prior to cream removal. The cream is then removed from all sites and the Chromameter measurements for the pharmacodynamic responses of the topical corticosteroid will be carried out at 0, 2, 4, 6, 19 and 24 hours following removal. Subjects who meet the inclusion and exclusion criteria will be included in this study. Pre and post study laboratory tests will be performed along with an ECG and medical evaluation. A follow up visit will also be completed to assess for safety.
Sponsors
Zenith Technology Corp Ltd
Study design
Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Males or females In good general health Aged between 18-55 years of age inclusive BMI between 18 and 33 inclusive Laboratory tests within normal ranges or assessed not significant by the Clinical Investigator Normal ECG
Exclusion criteria
Clinically significant hypertension or circulatory disease and any clinically significant illness during the last four weeks prior to the entry into this study. Caffeine intake greater than 500 mg per day prior to this study. Who have been on a special diet, especially a low salt and/or fluid diet, during the 2 weeks prior to the first study day. Use of topical Dermatologic drug therapy on ventral forearms. Adverse reactions to topical or systemic corticosteroids. Who require shaving of the ventral forearms. Use of any vasoactive medication, prescription or over the counter that could modulate blood flow. Use of any prescription medication within 2 weeks preceding entry into the study Any obvious difference in skin colour between arms or any scarring on the forearms. Females who are pregnant or lactating Significant medical condition that could in the Investigator's opinion interfere with the study, or put the subject at significant risk Participation in any drug or medical device study within 30 days of entering this study
Outcome results
None listed